Pharma
sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Most Viewed Abstracts



Your Article Summary

See Latest Articles
(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Cell Therapeutics Completes Pixantrone NDA Submission and Requests Priority Review
Cell Therapeutics, 06/25/09

Cell Therapeutics, Inc. announced that it has completed the submission of the New Drug Application to the U.S. Food and Drug Administration for pixantrone to treat relapsed or refractory, aggressive non-Hodgkin's lymphoma. CTI requested priority review, which if granted could lead to an approval decision from the FDA in the fourth quarter of 2009. Pixantrone is currently available in Europe on a named-patient basis.


Today in Regulatory Issues...keeping you current

Retigabine Regulatory Update
GlaxoSmithKline, 11/03/09

Review calls for EHR action in Saskatchewan
Canadian Healthcare Technology, 11/20/09

New Drug Application Filed for Eldecalcitol, An Active Vitamin D3 Derivative
Chugai Pharmaceutical Co., 11/04/09

See All of Regulatory Issues

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address